NLNK NewLink Genetics Corporation

1.75
+0.03  (+2%)
Previous Close 1.72
Open 1.72
Price To Book 0.53
Market Cap 65143061
Shares 37,224,606
Volume 240,533
Short Ratio
Av. Daily Volume 436,946

SEC filingsSee all SEC filings

  1. 8-K - Current report 181214374
  2. 8-K - Current report 181186101
  3. 8-K - Current report 181171468
  4. 8-K - Current report 181161701
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181157948

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data presented at ASCO June 4, 2017. Abstract 105.
GDC-0919 and atezolizumab
Solid tumors
Phase 2 poster presentation at ASCO June 5, 2017.
Indoximod + Sipuleucel-T
Metastatic castration resistant prostate cancer (mCRPC)
Phase randomization portion will not be initiated - noted April 15, 2018.
Indoximod in combination with KEYTRUDA or Opdivo - Indigo301
Melanoma - cancer
Phase 2 data presented at ASCO 2018. Primary endpoint not met.
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
Phase 3 failed to meet primary endpoint - May 2016
HyperAcute Pancreas - IMPRESS
Surgically resected pancreatic cancer
Phase 3 failed to show improvement in survival.
HyperAcute Pancreas - PILLAR
Pancreatic cancer
Phase 2 trial did not meet endpoints - noted June 2, 2017.
Indoximod + taxane
Cancer - breast
Phase 1b data to be presented at ASH December 2018.
Indoximod plus standard-of-care chemotherapy
Acute myeloid leukemia (AML)
Phase 1 updated data due 2019.
Indoximod in combination with chemotherapy and radiation
Diffuse intrinsic pontine glioma (DIPG)
Phase 1 initial data at SITC noted neither maximum tolerated dose (MTD), nor maximum biologically achievable dose (MBAD) has been reached.
NLG802
Solid tumors
Rolling BLA filing has commenced - noted November 13, 2018.
V920
Ebola

Latest News

  1. NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting
  2. Does NewLink Genetics Corporation’s (NASDAQ:NLNK) CEO Salary Compare Well With Others?
  3. Edited Transcript of NLNK earnings conference call or presentation 1-Nov-18 8:30pm GMT
  4. NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
  5. NewLink Genetics Presents Phase 1 Data Supporting Significantly Higher Exposure with Indoximod Prodrug, NLG802, and Biomarker Data from Two Phase 2 Trials Illustrating Indoximod’s Impact on the Tumor Microenvironment at SITC 2018
  6. NewLink Genetics Announces Publication of Abstracts for Presentation at the Society for Immunotherapy for Cancer (SITC) Conference
  7. Analysis: Positioning to Benefit within Mercury, Lincoln Electric, Sprint, Fred's, NewLink Genetics, and El Paso Electric — Research Highlights Growth, Revenue, and Consolidated Results
  8. Is the Options Market Predicting a Spike in NewLink Genetics (NLNK) Stock? (revised)
  9. NewLink Genetics (NLNK) Reports Q3 Loss, Lags Revenue Estimates
  10. NewLink: 3Q Earnings Snapshot
  11. NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
  12. NewLink Genetics Announces Oral Presentation at the 2018 American Society of Hematology (ASH) Annual Meeting
  13. NewLink Genetics (NLNK) Q3 Earnings Preview: What to Expect
  14. Analysis: Positioning to Benefit within ChemoCentryx, Armstrong Flooring, Kornit Digital, NewLink Genetics, Silvercorp Metals, and Halcon Resources — Research Highlights Growth, Revenue, and Consolidated Results
  15. What’s Ahead For NewLink Genetics Corporation (NASDAQ:NLNK)?
  16. NewLink Genetics to Participate in the Cantor Global Healthcare Conference

SEC Filings

  1. 8-K - Current report 181214374
  2. 8-K - Current report 181186101
  3. 8-K - Current report 181171468
  4. 8-K - Current report 181161701
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181157948
  6. 8-K/A [Amend] - Current report 181156098
  7. 8-K - Current report 181154246
  8. 8-K - Current report 181152418
  9. 8-K - Current report 181120338
  10. 8-K - Current report 181101264